Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Amortization of Deferred Charges: 2012-2023

Historic Amortization of Deferred Charges for Adma Biologics (ADMA) over the last 4 years, with Dec 2023 value amounting to $3.8 million.

  • Adma Biologics' Amortization of Deferred Charges fell 9.97% to $877,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.8 million, marking a year-over-year increase of 27.08%. This contributed to the annual value of $3.8 million for FY2023, which is 27.95% up from last year.
  • According to the latest figures from FY2023, Adma Biologics' Amortization of Deferred Charges is $3.8 million, which was up 27.95% from $3.0 million recorded in FY2022.
  • Adma Biologics' 5-year Amortization of Deferred Charges high stood at $3.8 million for FY2023, and its period low was $3.0 million during FY2022.
  • For the 2-year period, Adma Biologics' Amortization of Deferred Charges averaged around $3.4 million, with its median value being $3.4 million (2022).
  • Data for Adma Biologics' Amortization of Deferred Charges shows a peak YoY increased of 27.95% (in 2023) over the last 5 years.
  • Adma Biologics' Amortization of Deferred Charges (Yearly) stood at $3.0 million in 2022, then rose by 27.95% to $3.8 million in 2023.